全球各国bDMARD可及性不平等及其对疾病结局的影响:METEOR登记研究结果
基于METEOR数据库中12个国家至少贡献100例患者的20379例类风湿关节炎患者数据,分析国家社会经济地位(SES)、bDMARD使用量与疾病活动度之间的关系。结果显示国家SES与平均DAS28正相关但并不总是与HAQ评分相关;SES较低、处方报销规则更严格及bDMARD可负担性更差与bDMARD使用量较低相关;bDMARD使用量与疾病活动度负相关但关联至多中等。
要点
- 国家SES与平均DAS28正相关,但并不总是与HAQ评分相关。
- SES较低、处方报销规则更严格及bDMARD可负担性更差与bDMARD使用量较低相关。
- bDMARD使用量与疾病活动度负相关(与身体功能不相关),但关联至多中等。
核心结论
- 全球范围内类风湿关节炎患者的疾病活动度及bDMARD使用量存在差异,bDMARD使用量与疾病活动度之间的负向关系复杂并受多因素影响,包括但不限于国家SES、bDMARD可负担性及有效的处方报销规则。
研究设计与样本
- 从METEOR数据库提取至少贡献100例患者的国家数据,按国家计算所有可用患者末次访视的平均疾病结局,并向每国至少两名风湿科医生发放问卷询问DMARD价格、治疗可及性及处方报销的有效规定。
主要发现
- 来自12个国家的20379例患者数据显示,国家SES与测得的疾病活动度(平均DAS28)正相关,但并不总是与身体功能(HAQ评分)相关。
- 国家SES较低、bDMARD处方和报销规则更严格以及bDMARD可负担性更差与bDMARD使用量较低相关。
- bDMARD使用量与疾病活动度负相关(但与身体功能不相关),关联至多中等。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish in a global setting the relationships between countries' socioeconomic status (SES), measured biological disease modifying antirheumatic drug (bDMARD)-usage and disease outcomes. To assess if prescription and reimbursement rules and generic access to medication relates to a countries' bDMARD-usage. METHODS: Data on disease activity and drug use from countries that had contributed at least 100 patients were extracted from the METEOR database. Mean disease outcomes of all available patients at the final visit were calculated on a per-country basis. A questionnaire was sent to at least two rheumatologists per country inquiring about DMARD-prices, access to treatment and valid regulations for prescription and reimbursement. RESULTS: Data from 20 379 patients living in 12 different countries showed that countries' SES was positively associated with measured disease activity (meanDAS28), but not always with physical functioning (HAQ-score). A lower country's SES, stricter rules for prescription and reimbursement of bDMARDs as well as worse affordability of bDMARDs were associated with lower bDMARD-usage. bDMARD-usage was negatively associated with disease activity (although not with physical functioning), but the association was moderate at best. CONCLUSIONS: Disease activity in patients with rheumatoid arthritis as well as bDMARD-usage varies across countries worldwide. The (negative) relationship between countries' bDMARD-usage and level of disease activity is complex and under the influence of many factors, including-but not limited to-countries' SES, affordability of bDMARDs and valid prescription and reimbursement rules for bDMARDs.
引用
- Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis. 2018. PMID: 29980576. doi:10.1136/annrheumdis-2018-213289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。